Elevated proportion of circulating T effector memory cells is associated with early disease recurrence in oral squamous cell carcinoma – a case report 3958
Abstract Description Nearly half of oral squamous cell carcinoma (OSCC) patients experience disease recurrence within one year of treatment, with few predictive risk factors. There is a vital need to identify factors mediating early OSCC recurrence. Here we present two patients which exemplify these disparate outcomes and contrast known oral cancer risk factors. A 53-year-old never-smoker with no known risk factors was diagnosed with aggressive stage 4 OSCC. One year after treatment, he was hospitalized with a femur fracture secondary to extensive metastatic disease, after which he had a rapidly fulminant decline and died. In contrast, an 86-year-old with significant smoking history was diagnosed with similar stage 4 OSCC; two years after treatment she has no evidence of recurrence. Given known risk factors, our older patient with significant tobacco exposure was expected to have worse outcomes than a young, otherwise healthy patient. Instead, we found a negative association between disease outcomes and circulating proportion of highly differentiated T effector memory (HD TEMRA) cells; elevated levels of CD8+ HD TEMRA cells is significantly associated with poor disease control. While both patients had similar diseases and treatments, our 53-year-old patient had 42.8% CD8+ HD TEMRA cells vs 0.23% in our 86-year-old patient. We posit an immunologically aged phenotype, particularly a high HD TEMRA cell proportion, raises OSCC recurrence risk due to poor minimal residual disease control after surgery. Funding Sources Supported by 5T32CA272392-02, Emory Woodruff Center for Health in Aging, and Emory Winship Cancer Institute Topic Categories Tumor Immunology: Checkpoints, Prevention, and Treatment (TIPT)
Authors
- Dong M. Shin (ORCID: https://orcid.org/0000-0002-8245-4174)
- Brendan L. C. Kinney (ORCID: https://orcid.org/0000-0002-3516-3008)
- Jennifer H. Gross (ORCID: https://orcid.org/0000-0002-4241-4821)
- Nabil F. Saba (ORCID: https://orcid.org/0000-0003-4972-1477)
- H. Michael Baddour (ORCID: https://orcid.org/0000-0001-6330-1458)
- Nicole C. Schmitt (ORCID: https://orcid.org/0000-0002-0571-3531)
- Soumon Rudra (ORCID: https://orcid.org/0000-0002-1411-4880)
- Brianna Brammer (ORCID: https://orcid.org/0000-0002-3042-7326)
- Mark W. McDonald (ORCID: https://orcid.org/0000-0003-3021-9356)
Institutions
- Emory University (US)
- Cancer Institute (WIA) (IN)
Publication Details
- Journal
- The Journal of Immunology
- Published
- 2025-11-01
- DOI
- https://doi.org/10.1093/jimmun/vkaf283.1699
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Emory University
- Defense Threat Reduction Agency
- Winship Cancer Institute